StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) in a report released on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.
Separately, Cantor Fitzgerald boosted their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an overweight rating in a research note on Thursday, August 1st.
View Our Latest Research Report on Vanda Pharmaceuticals
Vanda Pharmaceuticals Stock Performance
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. The firm had revenue of $50.47 million for the quarter. On average, sell-side analysts predict that Vanda Pharmaceuticals will post -0.49 EPS for the current year.
Hedge Funds Weigh In On Vanda Pharmaceuticals
Large investors have recently made changes to their positions in the stock. ORG Wealth Partners LLC purchased a new stake in shares of Vanda Pharmaceuticals in the third quarter worth about $40,000. SG Americas Securities LLC boosted its stake in Vanda Pharmaceuticals by 88.5% in the third quarter. SG Americas Securities LLC now owns 20,402 shares of the biopharmaceutical company’s stock worth $96,000 after buying an additional 9,580 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 57.3% in the 2nd quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock valued at $9,003,000 after purchasing an additional 580,265 shares in the last quarter. Susquehanna Fundamental Investments LLC grew its stake in shares of Vanda Pharmaceuticals by 2.1% during the second quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company’s stock valued at $1,625,000 after buying an additional 5,994 shares during the last quarter. Finally, AQR Capital Management LLC grew its position in Vanda Pharmaceuticals by 181.7% during the 2nd quarter. AQR Capital Management LLC now owns 75,889 shares of the biopharmaceutical company’s stock worth $429,000 after acquiring an additional 48,945 shares during the last quarter. 88.14% of the stock is owned by institutional investors.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Further Reading
- Five stocks we like better than Vanda Pharmaceuticals
- Stock Market Upgrades: What Are They?
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- How is Compound Interest Calculated?
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.